Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.9K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.9K
Combinatorial Gene Control02:33

Combinatorial Gene Control

9.4K
Combinatorial gene control is the synergistic action of several transcriptional factors to regulate the expression of a single gene. The absence of one or more of these factors may lead to a significant difference in the level of gene expression or repression.
The expression of more than 30,000 genes is controlled by approximately 2000-3000 transcription factors. This is possible because a single transcription factor can recognize more than one regulatory sequence. The specificity in gene...
9.4K
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

3.8K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.9K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhancer of zeste 2 polycomb repressive complex 2 subunit overexpression suppresses apoptosis in canine T-cell lymphoma: an <i>in vitro</i> functional analysis.

Frontiers in veterinary science·2026
Same author

Niche-targeted therapy via YAP/TAZ activation enhances hematopoietic regeneration.

Blood·2026
Same author

Transferrin Receptor Marks a Foxp3-Low Treg-like Inflammatory T Cell Subset Associated with Disease Severity in HAM/TSP.

Pathogens (Basel, Switzerland)·2026
Same author

Polycomb repressive complex 2 insufficiency underlies myeloid leukemia in Down syndrome.

Blood·2026
Same author

Non-necroptotic MLKL function damages mitochondria and promotes hematopoietic stem cell aging.

Nature communications·2026
Same author

Impact of sentinel lymph node biopsy versus axillary lymph node dissection on shoulder range of motion in early rehabilitation after breast cancer surgery.

Breast cancer (Tokyo, Japan)·2026

Related Experiment Video

Updated: Jan 7, 2026

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes
10:26

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes

Published on: January 16, 2015

8.8K

Polycomb repressive complexes as therapeutic targets in hematologic malignancies.

Makoto Yamagishi1, Atsushi Iwama2, Issay Kitabayashi3

  • 1Laboratory of Viral Oncology and Genomics, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.

Experimental Hematology
|December 24, 2025
PubMed
Summary
This summary is machine-generated.

Polycomb repressive complexes (PRC1 and PRC2) regulate gene expression and are crucial for hematopoietic stem cell maintenance. Aberrant PRC1/2 activity drives hematologic malignancies, but dual EZH1/2 inhibitors show promise.

More Related Videos

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
09:16

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Published on: September 1, 2019

8.0K
Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

4.7K

Related Experiment Videos

Last Updated: Jan 7, 2026

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes
10:26

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes

Published on: January 16, 2015

8.8K
Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
09:16

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Published on: September 1, 2019

8.0K
Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

4.7K

Area of Science:

  • Epigenetics and transcriptional regulation
  • Hematopoiesis and stem cell biology
  • Cancer epigenetics and therapeutics

Background:

  • Polycomb group (PcG) proteins, organized into PRC1 and PRC2 complexes, control heritable gene silencing through histone modifications.
  • PRC1 and PRC2 play critical roles in hematopoietic stem cell (HSC) self-renewal and lineage specification.
  • Dysregulation of PRC1/2 components, including mutations in EZH2 and BCOR, is implicated in hematologic malignancies like AML, MDS, and lymphomas.

Purpose of the Study:

  • To review the roles of PRC1 and PRC2 in normal hematopoiesis and their involvement in hematologic malignancies.
  • To discuss the therapeutic targeting of PRC2, including EZH2-selective and dual EZH1/2 inhibitors, in lymphoid neoplasms.
  • To highlight challenges in PRC2-targeted therapy, such as resistance mechanisms, and the potential of dual inhibitors.

Main Methods:

  • Literature review and synthesis of existing research on Polycomb group proteins in hematopoiesis and cancer.
  • Analysis of the mechanisms of action for PRC1 and PRC2 in transcriptional repression and disease.
  • Evaluation of clinical data and therapeutic strategies involving EZH2 and dual EZH1/2 inhibitors.

Main Results:

  • PRC1 and PRC2 are essential for HSC maintenance, and their aberrant function drives various hematologic cancers.
  • Elevated H3K27me3 is a common epigenetic feature in lymphoid neoplasms, making PRC2 a viable therapeutic target.
  • Dual EZH1/2 inhibitors, like valemetostat, demonstrate efficacy in treating ATL and PTCL by overcoming resistance to EZH2-specific agents.

Conclusions:

  • Targeting the epigenome, particularly PRC2, is a promising strategy for treating hematologic malignancies.
  • Dual EZH1/2 inhibitors offer a potential therapeutic advantage over EZH2-selective inhibitors due to broader target engagement.
  • Continued development of dual EZH1/2 inhibitors is warranted to overcome therapeutic resistance and improve patient outcomes in lymphoid neoplasms.